{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:12:03Z","timestamp":1780405923406,"version":"3.54.1"},"reference-count":259,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017387","name":"JSS College of Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmc.2025.118393","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T22:55:34Z","timestamp":1758063334000},"page":"118393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Decades old glitazones still find niche in drug discoveries as PPAR-\u03b3 agonists: medicinal chemistry perspective, structure-activity relationships and therapeutic implications"],"prefix":"10.1016","volume":"131","author":[{"given":"P.","family":"Archana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Durai Ananda Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Vijaya Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshal","family":"Pundalik Tavanoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Deepikarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.R.","family":"Prashantha Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118393_bb0005","article-title":"Thiazolidinedione an auspicious scaffold as PPAR-\u03b3 agonist: its possible mechanism to manoeuvre against insulin resistant diabetes mellitus","volume":"11","author":"Basak","year":"2024","journal-title":"Eur J Med Chem Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0010","first-page":"49","article-title":"Epidemiology of diabetes mellitus. Transplantation, bioengineering, and regeneration of the endocrine pancreas","author":"Mekala","year":"2020","journal-title":"Elsevier"},{"key":"10.1016\/j.bmc.2025.118393_bb0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes \u2013 global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2019","journal-title":"J Epidemiol Glob Health"},{"key":"10.1016\/j.bmc.2025.118393_bb0020","unstructured":"IDF Diabetes Atlas | Global Diabetes Data & Statistics n.d. https:\/\/diabetesatlas.org\/ (accessed April 15, 2025)."},{"key":"10.1016\/j.bmc.2025.118393_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108086","article-title":"Mortality attributable to diabetes in 20\u201379 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"162","author":"Saeedi","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.bmc.2025.118393_bb0030","doi-asserted-by":"crossref","first-page":"21908","DOI":"10.1038\/s41598-023-49249-0","article-title":"Global trend analysis of diabetes mellitus incidence, mortality, and mortality-to-incidence ratio from 1990 to 2019","volume":"13","author":"Balooch Hasankhani","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0035","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.2147\/DMSO.S275898","article-title":"<p>obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications<\/p>","volume":"13","author":"Wondmkun","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.bmc.2025.118393_bb0040","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1172\/JCI10842","article-title":"Obesity and insulin resistance","volume":"106","author":"Kahn","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2025.118393_bb0045","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4239\/wjd.v6.i3.456","article-title":"Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus","volume":"6","author":"Tangvarasittichai","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.bmc.2025.118393_bb0050","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bmc.2025.118393_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/er.2007-0023","article-title":"Glucolipotoxicity: fuel excess and \u03b2-cell dysfunction","volume":"29","author":"Poitout","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bmc.2025.118393_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/ijms18010008","article-title":"Metabolic adaptation in obesity and type II diabetes: Myokines, Adipokines and Hepatokines","volume":"18","author":"Oh","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118393_bb0065","doi-asserted-by":"crossref","first-page":"16692","DOI":"10.1002\/jcp.28354","article-title":"Adipose-derived exosomes: a novel adipokine in obesity-associated diabetes","volume":"234","author":"Zhang","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.bmc.2025.118393_bb0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1570161117666190502103733","article-title":"Microvascular complications of type 2 diabetes mellitus","volume":"18","author":"Faselis","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.bmc.2025.118393_bb0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3810\/pgm.2012.11.2615","article-title":"Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae","volume":"124","author":"Campos","year":"2012","journal-title":"Postgrad Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0080","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of Hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmc.2025.118393_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.bmc.2025.118393_bb0090","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.2337\/dc12-0459","article-title":"Glucose derangements in very Young children with cystic fibrosis and pancreatic insufficiency","volume":"35","author":"Mozzillo","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmc.2025.118393_bb0095","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nm1025","article-title":"PPARs and the complex journey to obesity","volume":"10","author":"Evans","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0105","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2174\/138955707782331687","article-title":"Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis","volume":"7","author":"Niino","year":"2007","journal-title":"Mini-Rev Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/937843","article-title":"Targeting nuclear hormone receptors: PPAR \u03b1 agonists as potential disease-modifying drugs for rheumatoid arthritis","volume":"2011","author":"Shirinsky","year":"2011","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.bmc.2025.118393_bb0115","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmc.2025.118393_bb0120","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J Adv Pharm Technol Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0130","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.addr.2010.08.007","article-title":"Structural and functional insights into nuclear receptor signaling","volume":"62","author":"Jin","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmc.2025.118393_bb0135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tibs.2004.04.006","article-title":"Mechanism of the nuclear receptor molecular switch","volume":"29","author":"Nagy","year":"2004","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.bmc.2025.118393_bb0140","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118393_bb0145","series-title":"Peroxisome proliferator\u2013activated receptors. encyclopedia of exercise medicine in health and disease","first-page":"700","author":"Baker","year":"2012"},{"key":"10.1016\/j.bmc.2025.118393_bb0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0002-9149(01)02149-X","article-title":"Peroxisome proliferator-activated receptor-\u03b1 activation and high-density lipoprotein metabolism","volume":"88","author":"Fruchart","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.bmc.2025.118393_bb0155","doi-asserted-by":"crossref","unstructured":"Tontonoz P SB. Fat and beyond: the diverse biology of PPAR\u03b3 Annu Rev Biochem n.d.:289\u2013312.","DOI":"10.1146\/annurev.biochem.77.061307.091829"},{"key":"10.1016\/j.bmc.2025.118393_bb0160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1741-7007-7-38","article-title":"Expression of the peroxisome proliferator activated receptor \u03b3 gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes","volume":"7","author":"Fujiki","year":"2009","journal-title":"BMC Biol"},{"key":"10.1016\/j.bmc.2025.118393_bb0165","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of PPAR\u03b3","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118393_bb0170","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2010.13071","article-title":"Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels","author":"Yessoufou","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.bmc.2025.118393_bb0175","doi-asserted-by":"crossref","first-page":"8974","DOI":"10.3390\/ijms22168974","article-title":"PPARs-orchestrated metabolic homeostasis in the adipose tissue","volume":"22","author":"Sun","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118393_bb0180","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0185","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.isci.2018.06.012","article-title":"PPAR\u03b3 in complex with an antagonist and inverse agonist: a tumble and trap mechanism of the activation Helix","volume":"5","author":"Frkic","year":"2018","journal-title":"IScience"},{"key":"10.1016\/j.bmc.2025.118393_bb0195","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/cancers11121852","article-title":"Structure and function of the nuclear receptor superfamily and current targeted therapies of prostate Cancer","volume":"11","author":"Porter","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2025.118393_bb0200","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2337\/db07-0972","article-title":"Therapeutic potential of peroxisome proliferators\u2013activated receptor-\u03b1\/\u03b3 dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.bmc.2025.118393_bb0205","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/emm.2017.102","article-title":"Sex-specific regulation of immune responses by PPARs","volume":"49","author":"Park","year":"2017","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/6198628","article-title":"PPARs and the development of type 1 diabetes","volume":"2020","author":"Holm","year":"2020","journal-title":"PPAR Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0215","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2337\/dc11-2142","article-title":"Peroxisome proliferator\u2013activated receptor \u03b3 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes","volume":"35","author":"Zhang","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmc.2025.118393_bb0220","doi-asserted-by":"crossref","first-page":"12764","DOI":"10.1038\/s41598-020-69363-7","article-title":"PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis","volume":"10","author":"Sarhangi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0225","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2337\/diabetes.55.04.06.db05-0676","article-title":"The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism","volume":"55","author":"Jaziri","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.bmc.2025.118393_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/srep24472","article-title":"Association between PPAR-\u03b32 Pro12Ala genotype and insulin resistance is modified by circulating lipids in Mexican children","volume":"6","author":"Stryjecki","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0235","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3390\/biom12121832","article-title":"The potential roles of post-translational modifications of PPAR\u03b3 in treating diabetes","volume":"12","author":"Ji","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2025.118393_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102510","article-title":"The roles of PPAR\u03b3 and its agonists in autoimmune diseases: a comprehensive review","volume":"113","author":"Liu","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bmc.2025.118393_bb0245","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/818945","article-title":"Cross-talk between PPAR \u03b3 and insulin signaling and modulation of insulin sensitivity","volume":"2009","author":"Leonardini","year":"2009","journal-title":"PPAR Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0250","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/VHRM.S993","article-title":"Peroxisome proliferator-activated receptor-&gamma; agonists and diabetes: current evidence and future perspectives","volume":"4","author":"Di Marzio","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.bmc.2025.118393_bb0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review","volume":"13","author":"Grygiel-G\u00f3rniak","year":"2014","journal-title":"Nutr J"},{"key":"10.1016\/j.bmc.2025.118393_bb0260","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1210\/en.2003-0288","article-title":"Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors","volume":"144","author":"Lee","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.bmc.2025.118393_bb0265","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2025.118393_bb0270","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPAR\u03b3","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmc.2025.118393_bb0275","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI20514","article-title":"Obesity-induced inflammatory changes in adipose tissue","volume":"112","author":"Wellen","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2025.118393_bb0280","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.ATV.0000191663.12164.77","article-title":"Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes","volume":"26","author":"Blaschke","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bmc.2025.118393_bb0285","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/hr.2009.108","article-title":"Uncontrolled hypertension: beyond pharmacological treatment","volume":"32","author":"Pimenta","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0290","first-page":"L299","article-title":"Peroxisome proliferator activated receptor-\u03b3-rho-kinase interactions contribute to vascular remodeling after chronic intrauterine pulmonary hypertension","volume":"306","author":"Gien","year":"2014","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"10.1016\/j.bmc.2025.118393_bb0295","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1039\/D1RA08925K","article-title":"Thiazolidinedione derivatives as novel GPR120 agonists for the treatment of type 2 diabetes","volume":"12","author":"Wang","year":"2022","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2025.118393_bb0300","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/21623945.2020.1838186","article-title":"Revisiting PPAR\u03b3 as a new friend of GPR120 in the treatment of metabolic disorders","volume":"9","author":"Paschoal","year":"2020","journal-title":"Adipocyte"},{"key":"10.1016\/j.bmc.2025.118393_bb0305","first-page":"6","article-title":"Unlocking the potential of receptor-based approaches in diabetes treatment. BIO","author":"Patwekar","year":"2025","journal-title":"Integration"},{"key":"10.1016\/j.bmc.2025.118393_bb0310","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/amsad\/202298","article-title":"Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?","volume":"10","author":"Papaetis","year":"2025","journal-title":"Arch Med Sci \u2013 Atheroscler Dis"},{"key":"10.1016\/j.bmc.2025.118393_bb0320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2337\/dsi23-0012","article-title":"Pharmacological approaches to nonalcoholic fatty liver disease: current and future therapies","volume":"37","author":"Genua","year":"2024","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.bmc.2025.118393_bb0325","first-page":"2","article-title":"Pleiotropic effects of Glitazones: a double edge sword?","author":"Salomone","year":"2011","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118393_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.991059","article-title":"Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases","volume":"13","author":"Sharma","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118393_bb0335","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0340","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR\u03b32, a lipid-activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118393_bb0345","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","article-title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase","volume":"8","author":"Yamauchi","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0350","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","article-title":"Thiazolidinediones as antidiabetic agents: a critical review","volume":"77","author":"Nanjan","year":"2018","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0355","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18773\/austprescr.2004.059","article-title":"Experimental and clinical pharmacology: Thiazolidinediones - mechanisms of action","volume":"27","author":"Greenfield","year":"2004","journal-title":"Aust Prescr"},{"key":"10.1016\/j.bmc.2025.118393_bb0360","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0169-409X(02)00093-5","article-title":"Troglitazone: the discovery and development of a novel therapy for the treatment of type 2 diabetes mellitus","volume":"54","author":"Parker","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmc.2025.118393_bb0365","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/13543776.2014.1001738","article-title":"Thiazolidinedione compounds: a patent review (2010 \u2013 present)","volume":"25","author":"Desai","year":"2015","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2025.118393_bb0370","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00002018-200124120-00002","article-title":"Hepatotoxicity with Thiazolidinediones","volume":"24","author":"Scheen","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.bmc.2025.118393_bb0375","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ejmech.2016.12.020","article-title":"Thiazolidinediones and PPAR orchestra as antidiabetic agents: from past to present","volume":"126","author":"Yasmin","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0380","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder Cancer among diabetic patients treated with pioglitazone","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmc.2025.118393_bb0385","first-page":"170","article-title":"Rosiglitazone Revisited","author":"Nissen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0390","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.phrs.2007.08.002","article-title":"The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo","volume":"56","author":"Li","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0395","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/j.1523-1755.2005.00721.x","article-title":"Nuclear receptors and their coregulators in kidney","volume":"68","author":"Ruan","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.bmc.2025.118393_bb0400","first-page":"81","article-title":"Comparative study of efficacy and safety of Lobeglitazone versus pioglitazone as add on therapy to metformin and Vildagliptin in patients of type 2 diabetes mellitus","author":"Raman","year":"2023","journal-title":"Int J Pharm Sci Rev Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0405","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4093\/dmj.2020.0272","article-title":"Lobeglitazone: a novel thiazolidinedione for the Management of Type 2 diabetes mellitus","volume":"45","author":"Bae","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.bmc.2025.118393_bb0410","article-title":"Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice","volume":"13","author":"Choi","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2025.118393_bb0415","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/biom14020190","article-title":"PPAR\u03b3 modulators in lung Cancer: molecular mechanisms, clinical prospects, and challenges","volume":"14","author":"Zhang","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2025.118393_bb0420","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/cells9020352","article-title":"PPAR-mediated toxicology and applied pharmacology","volume":"9","author":"Xi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2025.118393_bb0425","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118393_bb0430","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through PPAR\u03b3 stimulation of ENaC-mediated renal salt absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0435","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2337\/dc05-2445","article-title":"The effect of pioglitazone on the liver","volume":"29","author":"Gastaldelli","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmc.2025.118393_bb0440","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2025.118393_bb0445","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0450","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118393_bb0455","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1038\/ncomms8443","article-title":"Pharmacological repression of PPAR\u03b3 promotes osteogenesis","volume":"6","author":"Marciano","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118393_bb0460","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1038\/srep09530","article-title":"Identification of a novel selective agonist of PPAR\u03b3 with no promotion of adipogenesis and less inhibition of osteoblastogenesis","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0465","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/cr.2010.13","article-title":"PPARs: diverse regulators in energy metabolism and metabolic diseases","volume":"20","author":"Wang","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0470","article-title":"Selective targeting of PPAR\u03b3 by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency","volume":"5","author":"Zheng","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0475","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1021\/jm101360s","article-title":"Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators","volume":"55","author":"Pirat","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0480","doi-asserted-by":"crossref","first-page":"267S","DOI":"10.3945\/ajcn.2009.28449E","article-title":"Selective peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) modulation as a strategy for safer therapeutic PPAR\u03b3 activation","volume":"91","author":"Higgins","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.bmc.2025.118393_bb0485","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1038\/s41598-017-14776-0","article-title":"Novel Benzylidene thiazolidinedione derivatives as partial PPAR\u03b3 agonists and their antidiabetic effects on type 2 diabetes","volume":"7","author":"Yasmin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2007\/32696","article-title":"Selective modulators of PPAR- <math> <mi>\u03b3<\/mi> <\/math> activity: molecular aspects related to obesity and side-effects","volume":"2007","author":"Zhang","year":"2007","journal-title":"PPAR Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0495","first-page":"5","article-title":"Identification of an alternative ligand-binding pocket in peroxisome proliferator-activated receptor gamma and its correlated selective agonist for promoting beige adipocyte differentiation","author":"Tian","year":"2024","journal-title":"MedComm (Beijing)"},{"key":"10.1016\/j.bmc.2025.118393_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8360919","article-title":"Discovery of novel insulin sensitizers: promising approaches and targets","volume":"2017","author":"Chen","year":"2017","journal-title":"PPAR Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0505","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2174\/1389557518666181026092029","article-title":"2,4-Thiazolidinediones as PTP 1B inhibitors: a Mini review (2012-2018)","volume":"19","author":"Verma","year":"2019","journal-title":"Mini-Rev Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0510","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.biopha.2018.08.124","article-title":"Synthesis and evaluation of thiazolidine-2,4-dione\/benzazole derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B): Antihyperglycemic activity with molecular docking study","volume":"107","author":"Hidalgo-Figueroa","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2025.118393_bb0515","first-page":"183","article-title":"Metal and nonmetal assisted synthesis of Six-membered heterocycles","author":"Kaur","year":"2020","journal-title":"Elsevier"},{"key":"10.1016\/j.bmc.2025.118393_bb0520","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/cmdc.202100177","article-title":"Thiazolidinediones: an in\u2013depth study of their synthesis and application to medicinal chemistry in the treatment of diabetes mellitus","volume":"16","author":"Long","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2025.118393_bb0525","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2174\/1570159X19666211109141330","article-title":"Advances in PPARs molecular dynamics and Glitazones as a repurposing therapeutic strategy through mitochondrial redox dynamics against neurodegeneration","volume":"20","author":"Durai","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.bmc.2025.118393_bb0530","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bcp.2017.07.012","article-title":"Study of new interactions of glitazone\u2019s stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins","volume":"142","author":"\u00c1lvarez-Almaz\u00e1n","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2025.118393_bb0535","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.bmcl.2010.01.125","article-title":"Novel glitazones: design, synthesis, glucose uptake and structure\u2013activity relationships","volume":"20","author":"Kumar","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118393_bb0540","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1101\/gad.1263305","article-title":"Corepressors selectively control the transcriptional activity of PPAR\u03b3 in adipocytes","volume":"19","author":"Guan","year":"2005","journal-title":"Genes Dev"},{"key":"10.1016\/j.bmc.2025.118393_bb0545","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1021\/jm9605694","article-title":"Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone","volume":"39","author":"Tanis","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0550","first-page":"1","article-title":"Targeting peroxisome proliferator-activated receptors using Thiazolidinediones: strategy for Design of Novel Antidiabetic Drugs","volume":"2017","author":"Thangavel","year":"2017","journal-title":"Int J Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0555","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1021\/acsomega.4c11128","article-title":"From Apo to ligand-bound: unraveling PPAR\u03b3-LBD conformational shifts via advanced molecular dynamics","volume":"10","author":"Falbo","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2025.118393_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-025-57325-4","article-title":"Ligand efficacy shifts a nuclear receptor conformational ensemble between transcriptionally active and repressive states","volume":"16","author":"MacTavish","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118393_bb0565","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1248\/bpb.b21-00263","article-title":"Insights into dynamic mechanism of ligand binding to peroxisome proliferator-activated receptor \u03b3 toward potential pharmacological applications","volume":"44","author":"Miyamae","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bmc.2025.118393_bb0570","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1254\/jphs.FP0050578","article-title":"FK614, a novel peroxisome proliferator-activated receptor \u03b3 modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators","volume":"99","author":"Fujimura","year":"2005","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.bmc.2025.118393_bb0575","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1073\/pnas.96.11.6102","article-title":"A peroxisome proliferator-activated receptor \u03b3 ligand inhibits adipocyte differentiation","volume":"96","author":"Oberfield","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2025.118393_bb0580","first-page":"87","article-title":"Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (&#947;) agonist. Mini-reviews","volume":"12","author":"Agrawal","year":"2012","journal-title":"Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0585","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10822-015-9831-x","article-title":"Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands","volume":"29","author":"Lewis","year":"2015","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmc.2025.118393_bb0590","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.3390\/ijms15057651","article-title":"Molecular modelling study of the PPAR? Receptor in relation to the mode of action\/adverse outcome pathway framework for liver steatosis","volume":"15","author":"Tsakovska","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118393_bb0595","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0192623307311757","article-title":"Urothelial carcinogenesis in the urinary bladder of rats treated with Naveglitazar, a \u03b3-dominant PPAR \u03b1\/\u03b3 agonist: lack of evidence for urolithiasis as an inciting event","volume":"36","author":"Long","year":"2008","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.bmc.2025.118393_bb0600","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.3390\/ijms19082189","article-title":"The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development","volume":"19","author":"Hong","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118393_bb0605","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jceh.2021.03.012","article-title":"Safety and efficacy of Saroglitazar in nonalcoholic fatty liver patients with diabetic dyslipidemia\u2014a prospective, interventional, pilot study","volume":"12","author":"Rajesh","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.bmc.2025.118393_bb0610","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/FJC.0000000000000891","article-title":"The Glitazars paradox: cardiotoxicity of the metabolically beneficial dual PPAR\u03b1 and PPAR\u03b3 activation","volume":"76","author":"Kalliora","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.bmc.2025.118393_bb0615","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jacc.2010.01.008","article-title":"High-density lipoprotein and coronary heart disease","volume":"55","author":"Natarajan","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bmc.2025.118393_bb0620","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.4155\/fmc-2020-0192","article-title":"Unearthing novel Thiazolidinone building blocks as carboxylic acid Bioisosteres","volume":"12","author":"Scanlon","year":"2020","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0625","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/jhet.3514","article-title":"Thiazolidinones: synthesis, reactivity, and their biological applications","volume":"56","author":"Nirwan","year":"2019","journal-title":"J Heterocyclic Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0630","first-page":"1","article-title":"Optimized synthesis and characterization of Thiazolidine-2, 4-Dione for pharmaceutical application. MOJ Bioorganic & Organic","author":"Alves Palma","year":"2017","journal-title":"Chemistry"},{"key":"10.1016\/j.bmc.2025.118393_bb0635","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jhet.5570430413","article-title":"Microwave induced synthesis of the thiazolidine-2,4-dione motif and the efficient solvent free-solid phase parallel syntheses of 5-benzylidene-thiazolidine-2,4-dione and 5-benzylidene-2-thioxo-thiazolidine-4-one compounds","volume":"43","author":"Kumar","year":"2006","journal-title":"J Heterocyclic Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0640","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1021\/op990197j","article-title":"The development of a Manufacturable synthesis of LY213829","volume":"4","author":"Slattery","year":"2000","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmc.2025.118393_bb0645","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13065-017-0357-2","article-title":"Biological potential of thiazolidinedione derivatives of synthetic origin","volume":"11","author":"Sucheta","year":"2017","journal-title":"Chem Cent J"},{"key":"10.1016\/j.bmc.2025.118393_bb0650","first-page":"773","article-title":"Design, synthesis and characterization of some novel thiazolidine-2,4-dione derivatives as antidiabetic agents","volume":"78","author":"Kadium","year":"2022","journal-title":"Acta Pol Pharm Drug Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0655","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1570193X19666220331155705","article-title":"Recent approaches in the synthesis of 5-Arylidene-2,4-thiazolidinedione derivatives using Knoevenagel condensation","volume":"20","author":"Paul","year":"2023","journal-title":"Mini Rev Org Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0660","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.ultsonch.2014.04.013","article-title":"Sonochemistry: a good, fast and clean method to promote the synthesis of 5-arylidene-2,4-thiazolidinediones","volume":"21","author":"Drawanz","year":"2014","journal-title":"Ultrason Sonochem"},{"key":"10.1016\/j.bmc.2025.118393_bb0665","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s00044-011-9792-0","article-title":"Novel glitazones: glucose uptake and cytotoxic activities, and structure\u2013activity relationships","volume":"21","author":"Prashantha Kumar","year":"2012","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0670","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ejmech.2010.12.019","article-title":"Synthesis, glucose uptake activity and structure\u2013activity relationships of some novel glitazones incorporated with glycine, aromatic and alicyclic amine moieties via two carbon acyl linker","volume":"46","author":"Kumar","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.jics.2023.101100","article-title":"Design, synthesis and anti-hyperglycemic assessments of novel 5-benzylidenethiazolidine-2,4-dione derivatives as PPAR-\u03b3 agonist","volume":"100","author":"Ali","year":"2023","journal-title":"J Indian Chem Soc"},{"key":"10.1016\/j.bmc.2025.118393_bb0680","doi-asserted-by":"crossref","first-page":"19869","DOI":"10.1038\/s41598-023-47157-x","article-title":"Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-\u03b3 agonists","volume":"13","author":"Najmi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0685","doi-asserted-by":"crossref","first-page":"s98","DOI":"10.5530\/ijper.57.1s.11","article-title":"Synthesis, antidiabetic evaluation and molecular docking studies of Thiazolidine-2,4-Dione analogues","volume":"57","author":"Pardeshi","year":"2023","journal-title":"Ind J Pharm Educ Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0690","first-page":"5068","article-title":"Synthesis of some novel 2,4-thiazolidinedione derivatives and their biological screening as antidiabetic agents","author":"S.K. JIWANE* VKSKPN and SKP.","year":"2009","journal-title":"Asian J Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0695","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.compbiolchem.2017.02.004","article-title":"Rational design and synthesis of some PPAR-\u03b3 agonists: substituted benzylideneamino-benzylidene-thiazolidine-2,4-diones","volume":"67","author":"Chhajed","year":"2017","journal-title":"Comput Biol Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128804","article-title":"Synthesis, in vitro, in silico and in vivo hypoglycemic and lipid-lowering effects of 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones mediated by dual PPAR \u03b1\/\u03b3 modulation","volume":"70","author":"Madrigal-Angulo","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118393_bb0705","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/14756366.2019.1608197","article-title":"Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers","volume":"34","author":"Huiying","year":"2019","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0710","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0960-894X(03)00257-9","article-title":"5-aryl thiazolidine-2,4-diones as selective PPAR\u03b3 agonists","volume":"13","author":"Koyama","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118393_bb0715","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s11224-020-01500-4","article-title":"De-novo design and synthesis of conformationally restricted thiazolidine-2,4-dione analogues: highly selective PPAR-\u03b3 agonist in search of anti-diabetic agent","volume":"31","author":"Chhajed","year":"2020","journal-title":"Struct Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0720","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/S0960-894X(03)00505-5","article-title":"5-aryl thiazolidine-2,4-diones: discovery of PPAR dual \u03b1\/\u03b3 agonists as antidiabetic agents","volume":"13","author":"Desai","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118393_bb0725","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.bmcl.2004.12.041","article-title":"Synthesis and pharmacological evaluation of substituted 5-[4-[2-(6,7-dimethyl-1,2,3,4-tetrahydro-2-oxo-4-quinoxalinyl)ethoxy]phenyl]methylene*******thiazolidine-2,4-dione derivatives as potent euglycemic and hypolipidemic agents","volume":"15","author":"Gupta","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118393_bb0730","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1021\/bc025606m","article-title":"Vanadyl\u2212thiazolidinedione combination agents for diabetes therapy","volume":"14","author":"Storr","year":"2003","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0735","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bioorg.2017.11.010","article-title":"Design, synthesis and molecular docking of thiazolidinedione based benzene sulphonamide derivatives containing pyrazole core as potential anti-diabetic agents","volume":"76","author":"MohdJ","year":"2018","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0740","first-page":"351","article-title":"Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-\u03b3 modulators","author":"MohdJ","year":"2018","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bmc.2025.118393_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103271","article-title":"Synthesis and biological evaluation of thiazolidine-2,4-dione-pyrazole conjugates as antidiabetic, anti-inflammatory and antioxidant agents","volume":"92","author":"Bansal","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0750","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bioorg.2018.09.034","article-title":"Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-\u03b3 agonists and anti-inflammatory COX-2 selective inhibitors","volume":"82","author":"Abdellatif","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107760","article-title":"Discovery of novel thiazole derivatives containing pyrazole scaffold as PPAR-\u03b3 agonists, \u03b1-glucosidase, \u03b1-amylase and COX-2 inhibitors; design, synthesis and in silico study","volume":"152","author":"Fadaly","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0760","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1016\/j.jscs.2012.10.010","article-title":"Design and synthesis of novel thiazolidine-2,4-diones as hypoglycemic agents","volume":"20","author":"Datar","year":"2016","journal-title":"J Saudi Chem Soc"},{"key":"10.1016\/j.bmc.2025.118393_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105342","article-title":"Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPAR\u03b3","volume":"116","author":"Sun","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116939","article-title":"Reversal of insulin resistance to combat type 2 diabetes mellitus by newer thiazolidinedione\u2019s in fructose induced insulin resistant rats","volume":"280","author":"Ranade","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0775","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.14233\/ajchem.2020.22565","article-title":"Design, synthesis and characterization of pyrimidine based thiazolidinedione derivatives","volume":"32","author":"Sharma","year":"2020","journal-title":"Asian J Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106449","article-title":"Synthesis, in-silico studies and biological evaluation of pyrimidine based thiazolidinedione derivatives as potential anti-diabetic agent","volume":"134","author":"Amin","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0785","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-827X(02)01241-7","article-title":"Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives\u2014fifth communication: flavonyl benzyl substituted 2,4-thiazolidinediones","volume":"58","author":"Tun\u00e7bilek","year":"2003","journal-title":"Il Farmaco"},{"key":"10.1016\/j.bmc.2025.118393_bb0790","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1016\/j.bmc.2008.05.059","article-title":"Synthesis and biological activity of some new flavonyl-2,4-thiazolidinediones","volume":"16","author":"Bozda\u011f-D\u00fcndar","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0795","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1038\/s41598-025-88944-y","article-title":"CADD based designing and biological evaluation of novel triazole based thiazolidinedione coumarin hybrids as antidiabetic agent","volume":"15","author":"Sharma","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106235","article-title":"Coumarin-4-yl-1,2,3-triazol-4-yl-methyl-thiazolidine-2,4-diones: synthesis, glucose uptake activity and cytotoxic evaluation","volume":"130","author":"Metre","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0805","first-page":"834","article-title":"Synthesis, characterization, biological evaluation and docking of Coumarin coupled thiazolidinedione derivatives and its Bioisosteres as PPAR\u03b3 agonists","volume":"8","author":"Shukla","year":"2012","journal-title":"Med Chem (Los Angeles)"},{"key":"10.1016\/j.bmc.2025.118393_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105162","article-title":"Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents","volume":"115","author":"Shakour","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0815","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cbdd.12140","article-title":"Synthesis, hypoglycaemic, hypolipidemic and ppar\u03b3 agonist activities of 5-(2-alkyl\/aryl-6-arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-thiazolidinediones","volume":"82","author":"Khazi","year":"2013","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2025.118393_bb0820","first-page":"25","article-title":"Thiazolidinediones as anti-cancer agents","volume":"6","author":"Blanquicett","year":"2008","journal-title":"Cancer Ther"},{"key":"10.1016\/j.bmc.2025.118393_bb0825","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pharep.2015.08.001","article-title":"Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-\u03b3 pathway","volume":"68","author":"Kole","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0830","doi-asserted-by":"crossref","DOI":"10.3892\/or.2020.7482","article-title":"Pioglitazone as a modulator of the chemoresistance of renal cell adenocarcinoma to methotrexate","author":"Pi\u0105tkowska\u2013chmiel","year":"2020","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0835","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.3892\/ol.2014.2553","article-title":"Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells","volume":"8","author":"Ninomiya","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.bmc.2025.118393_bb0840","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1210\/jc.2013-1106","article-title":"Efatutazone, an Oral PPAR-\u03b3 agonist, in combination with paclitaxel in anaplastic thyroid Cancer: results of a multicenter phase 1 trial","volume":"98","author":"Smallridge","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bmc.2025.118393_bb0845","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ejmech.2016.08.029","article-title":"Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents","volume":"124","author":"Sharma","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0850","doi-asserted-by":"crossref","first-page":"16226","DOI":"10.1039\/C8NJ03248C","article-title":"Synthesis and in vitro cytotoxicity evaluation of \u03b2-carboline-linked 2,4-thiazolidinedione hybrids: potential DNA intercalation and apoptosis-inducing studies","volume":"42","author":"Tokala","year":"2018","journal-title":"New J Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103522","article-title":"Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines","volume":"95","author":"Tilekar","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0860","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/ph15020226","article-title":"Design, molecular docking, synthesis, anticancer and anti-hyperglycemic assessments of Thiazolidine-2,4-diones bearing Sulfonylthiourea moieties as potent VEGFR-2 inhibitors and PPAR\u03b3 agonists","volume":"15","author":"Abdelgawad","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmc.2025.118393_bb0865","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13659-020-00293-7","article-title":"Natural products in cancer therapy: past, present and future","volume":"11","author":"Huang","year":"2021","journal-title":"Nat Prod Bioprospect"},{"key":"10.1016\/j.bmc.2025.118393_bb0870","doi-asserted-by":"crossref","first-page":"8367","DOI":"10.3390\/molecules27238367","article-title":"Natural products as anticancer agents: current status and future perspectives","volume":"27","author":"Naeem","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118393_bb0875","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.3390\/molecules29204957","article-title":"Thiazolidinedione-conjugated Lupeol derivatives as potent anticancer agents through a mitochondria-mediated apoptotic pathway","volume":"29","author":"Deng","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118393_bb0880","first-page":"4","article-title":"Design, synthesis, and biological evaluation of novel heterocyclic derivatives of 2,4-thiazolidine dione as anti-cancer agents","author":"Vunnam","year":"2025","journal-title":"Appl Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0885","doi-asserted-by":"crossref","first-page":"24101","DOI":"10.1038\/s41598-024-73793-y","article-title":"Design, synthesis and mechanistic study of N-4-Piperazinyl Butyryl thiazolidinedione derivatives of ciprofloxacin with anticancer activity via topoisomerase I\/II inhibition","volume":"14","author":"Aziz","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118393_bb0890","series-title":"Design, synthesis and biological evaluation of potent thiazolidinedione salicylic acid inhibitors against glyoxalase-I as potential anticancer agents","author":"Alomari","year":"2024"},{"key":"10.1016\/j.bmc.2025.118393_bb0895","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/978-1-4614-0653-2_19","article-title":"Neurodegeneration in diabetes mellitus","author":"Umegaki","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.bmc.2025.118393_bb0900","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molmed.2023.09.005","article-title":"Diabetes: a tipping point in neurodegenerative diseases","volume":"29","author":"Santiago","year":"2023","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bmc.2025.118393_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108542","article-title":"PINK1 and oxidative stress in lean and obese patients with type 2 diabetes mellitus","volume":"37","author":"Almeida","year":"2023","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.bmc.2025.118393_bb0910","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4103\/epj.epj_51_24","article-title":"Pink1 gene: a key player in the pathophysiology of type 2 diabetes mellitus","volume":"23","author":"Dinislam","year":"2024","journal-title":"Egypt Pharm J"},{"key":"10.1016\/j.bmc.2025.118393_bb0915","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/acschemneuro.1c00085","article-title":"Glitazones activate PGC-1\u03b1 signaling via PPAR-\u03b3: a promising strategy for Antiparkinsonism therapeutics","volume":"12","author":"Pa","year":"2021","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmc.2025.118393_bb0920","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.3390\/ijms24043264","article-title":"PPARs and their neuroprotective effects in Parkinson\u2019s disease: a novel therapeutic approach in \u03b1-synucleinopathy?","volume":"24","author":"P\u00e9rez-Segura","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118393_bb0925","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2174\/1389557521666210304112403","article-title":"Glitazones, PPAR-\u03b3 and neuroprotection","volume":"21","author":"Kumar","year":"2021","journal-title":"Mini-reviews Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb0930","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.3390\/ijms24043201","article-title":"Development of PPAR\u03b3 agonists for the treatment of Neuroinflammatory and neurodegenerative diseases: Leriglitazone as a promising candidate","volume":"24","author":"Pizcueta","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118393_bb0935","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s12640-019-00132-9","article-title":"Rational design, synthesis, and in vitro neuroprotective evaluation of novel Glitazones for PGC-1\u03b1 activation via PPAR-\u03b3: a new therapeutic strategy for neurodegenerative disorders","volume":"37","author":"Justin","year":"2020","journal-title":"Neurotox Res"},{"key":"10.1016\/j.bmc.2025.118393_bb0940","first-page":"14","article-title":"Two rationally identified novel Glitazones reversed the behavioral dysfunctions and exhibited neuroprotection through ameliorating brain cytokines and oxy-radicals in ICV-LPS Neuroinflammatory rat model","author":"Justin","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bmc.2025.118393_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133354","article-title":"Rational design, molecular docking, dynamic simulation, synthesis, PPAR-\u03b3 competitive binding and transcription analysis of novel glitazones","volume":"1265","author":"Kumar","year":"2022","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2025.118393_bb0950","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1021\/acsomega.2c07521","article-title":"Design and development of novel Glitazones for activation of PGC-1\u03b1 signaling via PPAR-\u03b3 Agonism: a promising therapeutic approach against Parkinson\u2019s disease","volume":"8","author":"Prabhakaran","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2025.118393_bb0955","doi-asserted-by":"crossref","first-page":"33247","DOI":"10.1039\/D4RA06330A","article-title":"Novel PPAR-\u03b3 agonists as potential neuroprotective agents against Alzheimer\u2019s disease: rational design, synthesis, in silico evaluation, PPAR-\u03b3 binding assay and transactivation and expression studies","volume":"14","author":"Hani","year":"2024","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2025.118393_bb0960","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4103\/ijem.IJEM_585_17","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"22","author":"Dharmalingam","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.bmc.2025.118393_bb0965","first-page":"10","article-title":"NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment","author":"Xia","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118393_bb0970","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dsi23-0015","article-title":"Nonalcoholic fatty liver disease in diabetes: a call to action","volume":"37","author":"Cusi","year":"2024","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.bmc.2025.118393_bb0975","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bmc.2025.118393_bb0980","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","article-title":"Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design","volume":"77","author":"Allen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2025.118393_bb0985","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118393_bb0990","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.69129","article-title":"Emerging therapies for non-alcoholic steatohepatitis (NASH): a comprehensive review of pharmacological and non-pharmacological approaches","author":"Kakde","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.bmc.2025.118393_bb0995","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.bmc.2025.118393_bb1000","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.bmc.2025.118393_bb1005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s43066-020-00043-x","article-title":"Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult","volume":"10","author":"Paul","year":"2020","journal-title":"Egypt Liver J"},{"key":"10.1016\/j.bmc.2025.118393_bb1010","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH \u2014 current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bmc.2025.118393_bb1015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis\u2020 \u2021","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.bmc.2025.118393_bb1020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3748\/wjg.v25.i2.163","article-title":"Current status, problems, and perspectives of non-alcoholic fatty liver disease research","volume":"25","author":"Tanaka","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bmc.2025.118393_bb1025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40360-021-00524-8","article-title":"Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis","volume":"22","author":"Akbari","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.bmc.2025.118393_bb1030","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/biom13081264","article-title":"Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease","volume":"13","author":"Kamata","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2025.118393_bb1035","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.3748\/wjg.v21.i13.3777","article-title":"Current pharmacological therapies for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"21","author":"Takahashi","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bmc.2025.118393_bb1040","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040356","article-title":"The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: a randomized controlled trial","volume":"103","author":"Khaliq","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.bmc.2025.118393_bb1045","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/jdi.14246","article-title":"Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial","volume":"15","author":"Ito","year":"2024","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.bmc.2025.118393_bb1050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12916-023-03129-6","article-title":"Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials","volume":"21","author":"Deng","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.bmc.2025.118393_bb1055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12876-023-02948-4","article-title":"Effect of Empagliflozin and pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial","volume":"23","author":"Attaran","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.bmc.2025.118393_bb1060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/2044090","article-title":"Effect and safety of pioglitazone-metformin tablets in the treatment of newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease in Shaanxi Province: a randomized, double-blinded, double-simulated multicenter study","volume":"2023","author":"Jianfang","year":"2023","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.bmc.2025.118393_bb1065","first-page":"14","article-title":"Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: a meta-analysis of randomized controlled trials","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bmc.2025.118393_bb1070","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3350\/cmh.2022.0330","article-title":"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis","volume":"29","author":"Park","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.bmc.2025.118393_bb1075","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031508","article-title":"Pioglitazone on nonalcoholic steatohepatitis: a systematic review and meta-analysis of 15 RCTs","volume":"101","author":"Zhao","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.bmc.2025.118393_bb1080","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.bmc.2025.118393_bb1085","first-page":"12","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a Meta-analysis","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bmc.2025.118393_bb1090","first-page":"12","article-title":"Efficacy of various hypoglycemic agents in the treatment of patients with nonalcoholic liver disease with or without diabetes: a network Meta-analysis","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bmc.2025.118393_bb1095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.bmc.2025.118393_bb1100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13293-020-00344-1","article-title":"Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism","volume":"12","author":"Yan","year":"2021","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.bmc.2025.118393_bb1105","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis","volume":"23","author":"Panunzi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bmc.2025.118393_bb1110","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdi.13457","article-title":"Favorable effect of sodium\u2013glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone","volume":"12","author":"Cho","year":"2021","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.bmc.2025.118393_bb1115","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3109\/09513590.2010.491572","article-title":"Thiazolinedione treatment in PCOS \u2013 an update","volume":"26","author":"Glintborg","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.bmc.2025.118393_bb1120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1592\/phco.25.2.244.56943","article-title":"Thiazolidinediones for treatment of polycystic ovary syndrome","volume":"25","author":"Stout","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bmc.2025.118393_bb1125","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0015-0282(01)02843-6","article-title":"Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone","volume":"76","author":"Cataldo","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bmc.2025.118393_bb1130","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1210\/jc.2003-031737","article-title":"Effect of the insulin sensitizer pioglitazone on insulin resistance, Hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome","volume":"89","author":"Brettenthaler","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bmc.2025.118393_bb1135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jpag.2013.09.015","article-title":"Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and Hyperandrogenism in Young women with polycystic ovary syndrome","volume":"27","author":"Stabile","year":"2014","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.bmc.2025.118393_bb1140","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1097\/MS9.0000000000001816","article-title":"A randomized controlled trial comparing pioglitazone and metformin prior to in vitro fertilization in polycystic ovary syndrome \u2013 associated infertile women: impact on pregnancy rates","volume":"86","author":"Taheripanah","year":"2024","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.bmc.2025.118393_bb1145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/9900213","article-title":"Comparative effectiveness of antidiabetic drugs as an additional therapy to metformin in women with polycystic ovary syndrome: a systematic review of metabolic approaches","volume":"2024","author":"Heidarpour","year":"2024","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.bmc.2025.118393_bb1150","first-page":"444","article-title":"Metformin & glitazones: do they really help PCOS patients?","volume":"56","author":"Pillai","year":"2007","journal-title":"J Fam Pract"},{"key":"10.1016\/j.bmc.2025.118393_bb1155","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.3390\/molecules27196763","article-title":"Thiazolidin-2,4-Dione scaffold: an insight into recent advances as antimicrobial, antioxidant, and hypoglycemic agents","volume":"27","author":"Kumar","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118393_bb1160","first-page":"13","article-title":"Medicinal perspective of 2,4-Thiazolidinediones derivatives: an insight into recent advancements","author":"Gupta","year":"2024","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.bmc.2025.118393_bb1165","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s11030-021-10302-7","article-title":"Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities","volume":"26","author":"Aziz","year":"2022","journal-title":"Mol Divers"},{"key":"10.1016\/j.bmc.2025.118393_bb1170","first-page":"40","article-title":"The new thiazolidine-2,4-dione-based hybrids with promising antimycobacterial activity: design, synthesis, biological evaluation, and drug interaction analysis","author":"Trotsko","year":"2025","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb1175","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13300-020-00948-1","article-title":"Comparative efficacy of Lobeglitazone versus pioglitazone on albuminuria in patients with type 2 diabetes mellitus","volume":"12","author":"Kim","year":"2021","journal-title":"Diabet Ther"},{"key":"10.1016\/j.bmc.2025.118393_bb1180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.59556\/japi.71.0445","article-title":"Randomized, double-blind, phase III trial of Lobeglitazone add-on to metformin in type 2 diabetes (SENSITIZE INDIA)","volume":"72","author":"Joshi","year":"2024","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.bmc.2025.118393_bb1185","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of Muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.bmc.2025.118393_bb1190","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3132\/dvdr.2007.042","article-title":"Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes","volume":"4","author":"Ratner","year":"2007","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.bmc.2025.118393_bb1195","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.scib.2021.03.019","article-title":"Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)","volume":"66","author":"Ji","year":"2021","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.bmc.2025.118393_bb1200","series-title":"Chiglitazar, the first pan-PPAR agonist approved globally, shows potential to treat metabolic dysfunction\u2013associated steatohepatitis in vitro and in vivo","author":"Deng","year":"2024"},{"key":"10.1016\/j.bmc.2025.118393_bb1205","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118393_bb1210","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2025.118393_bb1215","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2025.118393_bb1220","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.bmc.2025.118393_bb1225","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.bmc.2025.118393_bb1230","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118393_bb1235","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bmc.2025.118393_bb1240","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118393_bb1245","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.clinthera.2024.06.023","article-title":"Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and Dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study","volume":"46","author":"Cho","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.bmc.2025.118393_bb1250","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1111\/dom.15641","article-title":"Pioglitazone reduces serum ketone bodies in <scp>sodium-glucose cotransporter<\/scp> \u22122 inhibitor-treated non-obese type 2 diabetes: a single-Centre, randomized, crossover trial","volume":"26","author":"Yang","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bmc.2025.118393_bb1255","first-page":"13","article-title":"The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and Meta-analysis","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118393_bb1260","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmc.2025.118393_bb1265","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/00325481.2019.1670017","article-title":"Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes","volume":"131","author":"Lajara","year":"2019","journal-title":"Postgrad Med"},{"key":"10.1016\/j.bmc.2025.118393_bb1270","first-page":"11","article-title":"Prospect of sodium\u2013glucose co-transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes","author":"Yang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bmc.2025.118393_bb1275","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13098-025-01635-6","article-title":"Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Mousavi","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.bmc.2025.118393_bb1280","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2174\/156802608786413474","article-title":"Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress","volume":"8","author":"Cho","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb1285","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/138527211793797774","article-title":"Synthetic Thiazolidinediones: potential antidiabetic compounds","volume":"15","author":"Ortiz","year":"2011","journal-title":"Curr Org Chem"},{"key":"10.1016\/j.bmc.2025.118393_bb1290","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1874104501105010093","article-title":"Medicinal chemistry and actions of dual and Pan PPAR modulators","volume":"5","author":"Adeghate","year":"2011","journal-title":"Open Med Chem J"},{"key":"10.1016\/j.bmc.2025.118393_bb1295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1874467212666190111165015","article-title":"A contemporary overview of PPAR\u03b1\/\u03b3 dual agonists for the management of diabetic dyslipidemia","volume":"12","author":"Balakumar","year":"2019","journal-title":"Curr Mol Pharmacol"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:32:35Z","timestamp":1780403555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625003347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":259,"alternative-id":["S0968089625003347"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118393","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decades old glitazones still find niche in drug discoveries as PPAR-\u03b3 agonists: medicinal chemistry perspective, structure-activity relationships and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118393"}}